Published in Blood on September 15, 1999
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet (2011) 6.43
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med (2001) 5.66
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer (2009) 4.15
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest (2005) 3.99
Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-. J Exp Med (2011) 3.89
Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med (2004) 2.79
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.60
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest (2005) 2.40
Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov (2013) 2.31
Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A (2000) 2.24
Update on therapy of chronic lymphocytic leukemia. J Clin Oncol (2011) 2.19
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood (2012) 2.14
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood (2011) 2.09
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest (2004) 1.94
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood (2008) 1.93
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood (2014) 1.91
Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood (2009) 1.89
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood (2005) 1.89
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood (2010) 1.82
Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med (2008) 1.82
miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood (2014) 1.82
Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood (2010) 1.79
Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia (2010) 1.76
B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol (2013) 1.72
How I treat CLL up front. Blood (2009) 1.71
Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood (2009) 1.70
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood (2007) 1.69
Retracted The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest (2004) 1.68
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma (2011) 1.68
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood (2008) 1.67
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood (2008) 1.67
Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest (2012) 1.64
Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol (2009) 1.64
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood (2012) 1.61
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma (2012) 1.61
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.57
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. Blood (2015) 1.55
B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2006) 1.55
A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.54
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood (2014) 1.50
ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance. PLoS Genet (2014) 1.48
Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. Cell Cycle (2010) 1.47
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica (2010) 1.47
Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.45
Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification. J Exp Med (2002) 1.45
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood (2011) 1.44
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood (2009) 1.42
Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res (2008) 1.42
Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology (2005) 1.41
Prognostic relevance of MYD88 mutations in CLL: the jury is still out. Blood (2015) 1.41
Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A (2004) 1.40
Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med (2012) 1.40
In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood (2009) 1.40
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol (2016) 1.39
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med (2009) 1.35
CD38 and chronic lymphocytic leukemia: a decade later. Blood (2011) 1.33
A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med (2013) 1.32
Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol (2010) 1.30
Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med (2011) 1.29
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer (2008) 1.29
The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol (2008) 1.29
Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification. Blood (2006) 1.29
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer (2010) 1.28
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood (2008) 1.27
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica (2011) 1.25
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res (2012) 1.24
Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer (2009) 1.24
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am (2013) 1.22
Clinical consequences of defects in B-cell development. J Allergy Clin Immunol (2010) 1.19
Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res (2010) 1.18
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 1.18
Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood (2012) 1.16
Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res (2013) 1.15
Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia. BMC Bioinformatics (2010) 1.12
Novel agents for chronic lymphocytic leukemia. J Hematol Oncol (2013) 1.12
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol (2011) 1.12
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica (2009) 1.12
Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med (2010) 1.10
Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol (2012) 1.10
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia (2013) 1.08
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood (2015) 1.08
A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica (2009) 1.08
Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. Leukemia (2011) 1.07
Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol (2010) 1.07
Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. Cancer Genet (2011) 1.06
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia (2013) 1.05
Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics (2011) 1.05
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
Clinical staging of chronic lymphocytic leukemia. Blood (1975) 7.29
Expression of a receptor for IgM by human T cells in vitro. Eur J Immunol (1975) 5.05
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med (1994) 5.03
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Subpopulations of human T cells identified by receptors for immunoglobulins and mitogen responsiveness. J Immunol (1976) 4.64
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest (1998) 3.96
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol (1993) 3.39
Receptors for IgG molecules on human lymphocytes forming spontaneous rosettes with sheep red cells. Eur J Immunol (1975) 3.26
Ia-bearing T lymphocytes in man. Their identification and role in the generation of allogeneic helper activity. J Exp Med (1978) 3.18
Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J Immunol (2000) 3.13
Electrical and mechanical effects of BRL34915 in guinea-pig isolated trachealis. Br J Pharmacol (1986) 3.07
Genomic exclusion: a rapid means for inducing homozygous diploid lines in Tetrahymena pyriformis, syngen 1. Science (1967) 2.86
Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci U S A (1991) 2.81
High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum (2002) 2.45
Cytogenetics of genomic exclusion in Tetrahymena. Genetics (1967) 2.45
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood (1995) 2.43
Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. J Exp Med (1978) 2.39
Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood (1991) 2.35
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med (1995) 2.33
Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Circulation (1991) 2.18
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med (1989) 2.16
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol (1988) 2.06
Stimulation of human B lymphocytes by antibodies to IgM and IgG: functional evidence for the expression of IgG on B-lymphocyte surface membranes. Clin Immunol Immunopathol (1980) 2.00
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res (1996) 1.99
Induction of polyclonal antibody synthesis by human allogeneic and autologous helper factors. J Exp Med (1979) 1.98
Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med (2008) 1.95
Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses (1992) 1.94
Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J Biol Chem (1988) 1.80
Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am (1997) 1.79
T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol (1979) 1.74
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol (1998) 1.72
Electrophysiological and other aspects of the relaxant action of isoprenaline in guinea-pig isolated trachealis. Br J Pharmacol (1985) 1.69
Ten thousand years of head lice infection. Parasitol Today (2000) 1.68
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nat Med (2001) 1.66
Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol (2000) 1.64
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol (1994) 1.57
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer (2013) 1.57
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol (2000) 1.56
Genetic and epigenetic control of several isozymic systems in Tetrahymena. Ann N Y Acad Sci (1968) 1.55
Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses (1992) 1.53
Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia. Immunol Rev (1979) 1.53
The demonstration of acid alpha-naphthyl acetate esterase activity in human lymphocytes: usefulness as a T-cell marker. Cell Immunol (1978) 1.52
Two novel Italian CADASIL families from Central Italy with mutation CGC-TGC at codon 1006 in the exon 19 Notch3 gene. Neurol Sci (2006) 1.51
Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol (2001) 1.50
Human B-lymphotropic virus (human herpesvirus-6). J Virol Methods (1988) 1.48
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood (2001) 1.47
A study of lymphoma of large granular lymphocytes with modern modalities: report of two cases and review of the literature. Am J Hematol (1992) 1.44
Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis Rheum (1989) 1.44
Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol (1993) 1.43
The preparation of congenic strains of Tetrahymena. J Protozool (1971) 1.43
Characterization of human T-cell subpopulations as defined by specific receptors for immunoglobulins. Contemp Top Immunobiol (1978) 1.42
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer (2001) 1.41
Hapten-specific IgE antibody responses in mice. VII. Conversion of IgE "non-responder" strains to IgE "responders" by elimination of suppressor T cell activity. J Immunol (1977) 1.40
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
Conversion of systemic lupus erythematosus to common variable hypogammaglobulinemia. Am J Med (1989) 1.40
Ultrastructure and cytochemistry of human peripheral blood lymphocytes. Similarities between the cells of the third population and TG lymphocytes. Eur J Immunol (1980) 1.38
A new strategy for prenatal diagnosis in a sporadic haemophilia B family. Haemophilia (2001) 1.37
Receptors for IgM on certain human B lymphocytes. J Immunol (1977) 1.37
Hapten-specific IgE antibody responses in mice. VI. Selective enhancement of IgE antibody production by low doses of X-irradiation and by cyclophosphamide. J Immunol (1976) 1.36
CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood (1996) 1.35
Molecular studies of HHV-6. J Virol Methods (1988) 1.32
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia (2013) 1.31
Human T cell receptor for IgM: specificity for the pentameric Fc fragment. Eur J Immunol (1976) 1.30
Intersyngenic variations in the esterases of bacterized Paramecium aurelia. Biochem Genet (1971) 1.30
Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia (2002) 1.29
Evidence for a defect in "switch" T cells in patients with immunodeficiency and hyperimmunoglobulinemia M. N Engl J Med (1986) 1.29
A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia (2009) 1.27
Mechanical and electrical aspects of the relaxant action of aminophylline in guinea-pig isolated trachealis. Br J Pharmacol (1986) 1.27
The relaxant action of nicorandil in guinea-pig isolated trachealis. Br J Pharmacol (1986) 1.27
Human lymphocytes bearing "Ia-like" antigens; absence in patients with infantile agammaglobulinemia. J Immunol (1977) 1.26
Helper factors derived from autologous mixed lymphocyte cultures. Cell Immunol (1980) 1.26
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia (2009) 1.25
Immunoglobulin heavy chain variable region gene replacement As a mechanism for receptor revision in rheumatoid arthritis synovial tissue B lymphocytes. J Exp Med (2000) 1.25
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood (2000) 1.23
Bartonella species in bat flies (Diptera: Nycteribiidae) from western Africa. Parasitology (2012) 1.22
Regulation of the immune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J Immunol (1988) 1.21
In vitro selective expansion of allergen specific T cells from atopic patients. Clin Exp Immunol (1983) 1.21
The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. J Immunol (2000) 1.20